The estimated Net Worth of Venture Management Co. Vi, ... is at least $66.2 Milione dollars as of 11 September 2023. Venture Vi owns over 500,000 units of Alector stock worth over $63,060,677 and over the last 4 years Venture sold ALEC stock worth over $3,138,051.
Venture has made over 2 trades of the Alector stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture sold 500,000 units of ALEC stock worth $3,000,000 on 11 September 2023.
The largest trade Venture's ever made was selling 500,000 units of Alector stock on 11 September 2023 worth over $3,000,000. On average, Venture trades about 72,054 units every 168 days since 2020. As of 11 September 2023 Venture still owns at least 10,853,817 units of Alector stock.
You can see the complete history of Venture Vi stock trades at the bottom of the page.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... e Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: